Fecal Biomarkers: Non-invasive Diagnosis of Colorectal Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Sep 19

PMID 36119474

Authors

Qian Ding

Xiangxu Kong

Weilong Zhong

Wentian Liu

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the third most common cancer in the world in terms of morbidity and mortality, which brings great health hazards and economic burdens to patients and society. A fecal examination is an effective method for clinical examination and the most commonly used method for the census. It is simple, non-invasive, and suitable for large-scale population screening. With the development of molecular biology, lots of efforts have been made to discover new fecal biomarkers for the early screening of colorectal cancer. In this review, we summarize and discuss the recent advances of fecal biomarkers for CRC screening or diagnosis, including DNA biomarkers, RNA biomarkers, protein biomarkers, gut microbes and volatile organic compounds focusing on their diagnostic evaluation for CRC, which can provide a basis for the further development of new and effective CRC fecal screening and early diagnosis techniques.

Citing Articles

Volatile Organic Metabolites as Potential Biomarkers for Genitourinary Cancers: Review of the Applications and Detection Methods.

Holbrook K, Lee W Metabolites. 2025; 15(1).

PMID: 39852380 PMC: 11767221. DOI: 10.3390/metabo15010037.

Intratumor microbiota and colorectal cancer: Comprehensive and lucid review.

Zong Z, Zeng W, Li Y, Wang M, Cao Y, Cheng X Chin J Cancer Res. 2025; 36(6):683-699.

PMID: 39802896 PMC: 11724182. DOI: 10.21147/j.issn.1000-9604.2024.06.07.

Selection of optimal extraction and RT-PCR protocols for stool RNA detection of colorectal cancer associated immune genes.

Omran T, Madso I, Saether P, Bemanian V, Tunsjo H Sci Rep. 2024; 14(1):27468.

PMID: 39523395 PMC: 11551167. DOI: 10.1038/s41598-024-78680-0.

The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.

Barbosa J, Antoniosi Filho N Metabolomics. 2024; 20(5):113.

PMID: 39375265 DOI: 10.1007/s11306-024-02180-5.

Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.

Suri C, Pande B, Sahu T, Suhasini Sahithi L, Verma H J Clin Med. 2024; 13(13).

PMID: 38999541 PMC: 11242723. DOI: 10.3390/jcm13133977.

References

Arima K, Zhong R, Ugai T, Zhao M, Haruki K, Akimoto N . Western-Style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective Cohort Studies. Gastroenterology. 2022; 163(4):862-874. PMC: 9509428. DOI: 10.1053/j.gastro.2022.06.054. View

Hong S . Genetic and epigenetic alterations of colorectal cancer. Intest Res. 2018; 16(3):327-337. PMC: 6077299. DOI: 10.5217/ir.2018.16.3.327. View

Bastaminejad S, Taherikalani M, Ghanbari R, Akbari A, Shabab N, Saidijam M . Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer. Iran Biomed J. 2016; 21(2):106-13. PMC: 5274709. DOI: 10.18869/acadpub.ibj.21.2.106. View

Uppara M, Adaba F, Askari A, Clark S, Hanna G, Athanasiou T . A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer. World J Surg Oncol. 2015; 13:48. PMC: 4333243. DOI: 10.1186/s12957-015-0446-4. View

Wong S, Yu J . Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019; 16(11):690-704. DOI: 10.1038/s41575-019-0209-8. View

Keum N, Giovannucci E . Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019; 16(12):713-732. DOI: 10.1038/s41575-019-0189-8. View

Wohnhaas C, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K . Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohns Colitis 360. 2020; 2(1):otaa003. PMC: 7291945. DOI: 10.1093/crocol/otaa003. View

Khalili H, Gong J, Brenner H, Austin T, Hutter C, Baba Y . Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis. 2015; 36(9):999-1007. PMC: 4573660. DOI: 10.1093/carcin/bgv086. View

Limsui D, Vierkant R, Tillmans L, Wang A, Weisenberger D, Laird P . Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010; 102(14):1012-22. PMC: 2915616. DOI: 10.1093/jnci/djq201. View

10.

Ahmed F, Jeffries C, Vos P, Flake G, Nuovo G, Sinar D . Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics. 2009; 6(5):281-95. View

11.

Widlak M, Neal M, Daulton E, Thomas C, Tomkins C, Singh B . Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal Dis. 2018; 20(12):O335-O342. DOI: 10.1111/codi.14431. View

12.

Karczmarski J, Rubel T, Paziewska A, Mikula M, Bujko M, Kober P . Histone H3 lysine 27 acetylation is altered in colon cancer. Clin Proteomics. 2014; 11(1):24. PMC: 4071346. DOI: 10.1186/1559-0275-11-24. View

13.

Sokol H, Leducq V, Aschard H, Pham H, Jegou S, Landman C . Fungal microbiota dysbiosis in IBD. Gut. 2016; 66(6):1039-1048. PMC: 5532459. DOI: 10.1136/gutjnl-2015-310746. View

14.

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

15.

Ogino S, Nowak J, Hamada T, Milner Jr D, Nishihara R . Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology. Annu Rev Pathol. 2018; 14:83-103. PMC: 6345592. DOI: 10.1146/annurev-pathmechdis-012418-012818. View

16.

Zhu Y, Xu A, Li J, Fu J, Wang G, Yang Y . Fecal miR-29a and miR-224 as the noninvasive biomarkers for colorectal cancer. Cancer Biomark. 2016; 16(2):259-64. DOI: 10.3233/CBM-150563. View

17.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

18.

Yang C, Wu W, Yang Y, Yang X, Sun J, Zhang W . Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening. Oncol Lett. 2020; 20(2):1193-1200. PMC: 7377198. DOI: 10.3892/ol.2020.11674. View

19.

Eklof V, Lofgren-Burstrom A, Zingmark C, Edin S, Larsson P, Karling P . Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017; 141(12):2528-2536. PMC: 5697688. DOI: 10.1002/ijc.31011. View

20.

Thomas A, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M . Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 2019; 25(4):667-678. PMC: 9533319. DOI: 10.1038/s41591-019-0405-7. View